Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | GTAEXS617 |
| Trade Name | |
| Synonyms | GTAEXS 617|GTAEXS-617 |
| Drug Descriptions |
GTAEXS617 inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930). |
| DrugClasses | CDK7 Inhibitor 16 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + GTAEXS617 + Paclitaxel | Bevacizumab GTAEXS617 Paclitaxel | 0 | 1 |
| Fulvestrant + GTAEXS617 | Fulvestrant GTAEXS617 | 0 | 1 |
| GTAEXS617 | GTAEXS617 | 0 | 1 |